IP Library Granted Patent US 12,263,152
Granted Patent B2
US 12,263,152 · App. 18/217,172 · Granted Apr 1, 2025

Method of preventing and treating chemotherapy-induced alopecia

Inventors: Joaquin J. Jimenez (Miami, FL); John P. McCook (Frisco, TX)
Assignee: JJR&D, LLC
A61K31/327A61K9/0019A61K45/06A61P17/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,263,152
App. No.
18/217,172
Granted
Apr 1, 2025
Kind
B2
Abstract

Compositions and methods for treating alopecia, particularly chemotherapy-induced alopecia, using oxidizers or oxidants, pro-oxidant compounds, or activators of P53. Compositions comprising organic peroxides such as, cumene hydroperoxide, tert-Butyl hydroperoxide (t-BHP), hydrogen peroxide, benzoyl peroxide are preferred. Compositions may be applied subcutaneously, percutaneously, or topically. Most preferably, the compositions are applied to a treatment area prior to a round of chemotherapy to prevent or reduce hair loss in the treatment area.

Claims (30)

1. A method for reducing an amount of hair loss due to alopecia induced by a chemotherapeutic agent, the method comprising the step of:

providing a composition to a subject prior to the subject receiving a dose of the chemotherapeutic agent by applying the composition subcutaneously, percutaneously, or topically at or a near a treatment area on the subject;

wherein the subject does not have alopecia at the time of the providing step;

wherein the composition comprises benzoyl peroxide in an amount sufficient to provide a 0.1% to 15% w/w peroxide concentration based on a hydrogen peroxide equivalent peroxide value; and

wherein the benzoyl peroxide is the only active ingredient in the composition.

2. The method of claim 1 wherein the providing step comprises applying the composition percutaneously at or a near a treatment area on the subject; and

wherein the providing step is the only step in the method for reducing alopecia induced by a chemotherapeutic agent.

3. The method of claim 1 wherein the providing step comprises applying the composition topically; and

wherein the providing step is the only step in the method for reducing alopecia induced by a chemotherapeutic agent.

4. The method of claim 3 wherein the composition further comprises a carrier.

5. The method of claim 1 wherein the providing step comprises applying the composition subcutaneously; and

wherein the providing step is the only step in the method for reducing alopecia induced by a chemotherapeutic agent.

6. The method of claim 3 wherein the method reduces an amount of hair loss in the treatment area by at least 25% compared to an amount of loss in a second area of non-treatment that is similarly sized to the treatment area.

7. The method of claim 6 wherein the providing step comprises applying around 0.5 to 10% by weight of the benzoyl peroxide.

8. The method of claim 6 wherein the providing step is repeated at least once per day for a treatment period comprising at least 7 days before the subject receives the dose of the chemotherapeutic agent.

9. The method of claim 6 wherein the subject receives the dose of the chemotherapeutic agent multiple times over a period of time and wherein the providing step is repeated at least once per day for a treatment period comprising at least 7 days before the subject receives each dose of the chemotherapeutic agent.

10. The method of claim 9 wherein the chemotherapeutic agent comprises Vp-16, a taxane, Adriamycin, Cytoxan, cytosine arabinoside, or a combination thereof.

11. The method of claim 5 wherein the providing step is repeated at least once per day for a treatment period comprising at least 7 days before the subject receives the dose of the chemotherapeutic agent.

12. The method of claim 5 wherein the subject receives the dose of the chemotherapeutic agent multiple times over a period of time and wherein the providing step is repeated at least once per day for a treatment period comprising at least 7 days before the subject receives each dose of the chemotherapeutic agent.

13. The method of claim 3 wherein the providing step is repeated at least once per day for a treatment period comprising at least 7 days before the subject receives the dose of the chemotherapeutic agent.

14. The method of claim 13 wherein the subject receives the dose of the chemotherapeutic agent multiple times over a period of time and wherein the providing step is repeated at least once per day for a treatment period comprising at least 7 days before the subject receives each dose of the chemotherapeutic agent.

15. A method for reducing an amount of hair loss due to alopecia induced by a chemotherapeutic agent, the method comprising the step of:

providing a composition to a subject prior to the subject receiving a dose of the chemotherapeutic agent by applying the composition subcutaneously, percutaneously, or topically at or a near a treatment area on the subject;

wherein the composition comprises benzoyl peroxide in an amount sufficient to provide a 0.1% to 15% w/w peroxide concentration based on a hydrogen peroxide equivalent peroxide value; and

wherein the benzoyl peroxide is the only active ingredient in the composition.

16. The method of claim 15 wherein the providing step is repeated at least once per day for a treatment period comprising at least 3 days before the subject receives the dose of the chemotherapeutic agent.

17. The method of claim 15 wherein the providing step is repeated at least once per day for a treatment period comprising at least 7 days before the subject receives the dose of the chemotherapeutic agent.

18. The method of claim 1 wherein the providing step is repeated at least once per day for a treatment period comprising at least 3 days before the subject receives the dose of the chemotherapeutic agent.

19. The method of claim 1 wherein the providing step is repeated at least once per day for a treatment period comprising at least 7 days before the subject receives the dose of the chemotherapeutic agent.

20. The method of claim 1 wherein the benzoyl peroxide is in an amount sufficient to provide a 0.1% to 5% w/w peroxide concentration based on a hydrogen peroxide equivalent peroxide value.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2023
From: JIMENEZ, JOAQUIN J.; MCCOOK, JOHN P.
To: JJR&D, LLC
Reel/Frame 064328/0663 →
Continuity (2)
Provisional Application 63357783 · Jul 1, 2022
Related Publication 20240000743A1 · Jan 4, 2024
References Cited (55)
US 5877209A · Yunis · 1999 [cited by applicant]
US 6001378A · Desjonqueres · 1999 [cited by applicant]
US 6291443B1 · Jimenez · 2001 [cited by examiner]
US 7326420B2 · Burkhart et al. · 2008 [cited by applicant]
US 7682623B2 · Eini et al. · 2010 [cited by applicant]
US 9901637B2 · Jimenez et al. · 2018 [cited by applicant]
US 10493103B2 · Shanler et al. · 2019 [cited by applicant]
US 10758630B2 · Sample et al. · 2020 [cited by applicant]
US 11305016B2 · Jimenez et al. · 2022 [cited by applicant]
US 20030091602A1 · Witteler et al. · 2003 [cited by applicant]
US 20190343832A1 · Laberge et al. · 2019 [cited by applicant]
US 20210213021A1 · Brichta · 2021 [cited by examiner]
US 20220193383A1 · Barman · 2022 [cited by examiner]
WO WO2011032159 · 2011 [cited by applicant]
WO WO2018105941 · 2018 [cited by applicant]
WO WO2022035147 · 2022 [cited by applicant]
Mayo Clinic Staff, Chemotherapy and Hair Loss: What to expect during treatment, Feb. 26, 2022 (Year: 2022). [cited by examiner]
Itoh, Tomohiro et al., Cisplatin induces production of reative oxygen species via NADPH oxidase activation in human prostate cancer cells; Free Radical Research; Sep. 2011; 45(9): 1033-1039. [cited by applicant]
Jung, Byung-Jin et al., Dysregulation of NRF2 in Cancer: from Molecular Mechanisms to Therapeutic Opportunities; Biomolecules & Therapeutics; Dec. 7, 2017; Republic of Korea. [cited by applicant]
Zhang, Yusheng et al., Mild oxidative stress protects against chemotherapy-induced hair loss; Frontiers in Oncology; Jan. 10, 2023; Miami, Florida. [cited by applicant]
Saltsman, Jason A. et al., A Human Organoid Model of Aggressive Hepatoblastoma for Disease Modeling and Drug Testing. Cancers (Basel) . Sep. 18, 2020;12(9):2668. doi: 10.3390/cancers12092668. [cited by applicant]
Benz, Christopher C. et al., Ageing, oxidative stress and cancer: paradigms in parallax; Nat Rev Cancer; Nov. 2008; 8(11): 875-879; Novato, California. [cited by applicant]
Bao, Yi et al., Angiopoietin-like protein 3 blocks nuclear import of FAK and contributes to sorafenib response, Br J Cancer . Aug. 2018;119(4):450-461. doi: 10.1038/s41416-018-0189-4. Epub Jul. 23, 2018. [cited by applicant]
Chen, Shuo et al., Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site, Cancer Cell Feb. 8, 2021;39(2):225-239.e8. doi: 10.1016/j.ccell.2020.11.013. Epub Dec. 24, 2020. [cited by applicant]
Vessey, Donald A. et al., Characterization of the oxidative stress initiated in cultured human keratinocytes by treatment with peroxides. J Invest Dermatol. 1992;99:859-63. [cited by applicant]
Rees, Matthew G. et al., Correlating chemical sensitivity and basal gene expression reveals mechanism of action, Nat Chem Biol. Feb. 2016; 12(2):109-16. doi: 10.1038/nchembio.1986. Epub Dec. 14, 2015. [cited by applicant]
Punzi, Simona et al., Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs, Cells. Jun. 18, 2019;8(6):605. doi: 10.3390/c… [cited by applicant]
Zhang, et al., Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo, Blood Adv. Feb. 8, 2022;6(3):891-901. doi: 10.1182/bloodadvances.2021006156. [cited by applicant]
Tobin, et al., Graying: gerontobiology of the hair follicle pigmentary unit. Exp Gerontol. 2001;36:29-54. [cited by applicant]
De Vries, Gerda et al., Establishment and characterisation of testicular cancer patient-derived xenograft models for preclinical evaluation of novel therapeutic strategies, Sci Rep. Nov. 3, 2020;10(1):18938. doi: 10.103… [cited by applicant]
Luan, Jinwei et al., Identification of differentially expressed genes associated with the enhancement of X-ray susceptibility by RITA in a hypopharyngeal squamous cell carcinoma cell line (FaDu), Radiol Oncol. Feb. 22, … [cited by applicant]
Naito, A et al., Lipid peroxides induce early onset of catagen phase in murine hair cycles. Int J Mol Med. 2008;22:725-9. [cited by applicant]
Balaban Robert S., et al., Mitochondria, oxidants, and aging. Cell. 2005;120:483-95. [cited by applicant]
Aberuyi, N., et al. Negative value of CD10 -/CD34 - immunophenotype in pediatric leukemia and development of a related cell line model for investigating drug resistance, Clin Transl Oncol. Jan. 5, 2022. doi: 10.1007/s12… [cited by applicant]
Rees, Martin D. et al., Oxidative damage to extracellular matrix and its role in human pathologies. Free Radic Biol Med. 2008;44:1973-2001. [cited by applicant]
Tisma, Vesna et al., Oxidative stress and ferritin expression in the skin of patients with rosacea. J Am Acad Dermatol. 2009;60:270-6. [cited by applicant]
Spencer JD et al., Oxidative stress via hydrogen peroxide affects proopiomelanocortin peptides directly in the epidermis of patients with vitiligo. J Invest Dermatol. 2007;127:411-20. [cited by applicant]
Carugo, Alessandro et al., p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell. Feb. 11, 2019;35(2):204-220.e9. doi: 10.1016/j.ccell.2019.01.006. [cited by applicant]
Botchkarev, V.A., et al., (2000). p53 is essential for chemotherapy-induced hair loss. Cancer research, 60(18), 5002-5006. PMID:11016618. [cited by applicant]
Piccini, I. et al., (2022). Peroxisome proliferator-activated receptor-γ signalling protects hair follicle stem cells from chemotherapy-induced apoptosis and epithelial-mesenchymal transition. British Journal of Dermato… [cited by applicant]
Skalniak, Lukasz et al., Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells, Cancers (Basel). Oct. 24, 2018;10(11):396. doi: 10.3390/cancers10110396. [cited by applicant]
Hussein et al., protection from Chemotherapy-induced alopecia in a rat model, Science, vol. 249, issued Sep. 28, 1990, pp. 1564-1566 entire document. [cited by applicant]
Wood, JM et al., Senile hair graying: H2O2-mediated oxidative stress affects human hair color by blunting methionine sulfoxide repair. FASEB J. 2009;23:2065-75. [cited by applicant]
Isermann, Tamara et al., Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosity, Nat Commun. Jun. 29, 2021;12(1):4019. doi: 10.1038/s41467-021-24064-1. [cited by applicant]
Ng, Samuel Y. et al., Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models, Nat Commun. May 22, 2018;9(1):2024. doi: 10.1038/s41467-018-04356-9. [cited by applicant]
Prager, Briana C. et al., The Meningioma Enhancer Landscape Delineates Novel Subgroups and Drives Druggable Dependencies. Cancer Discov. Nov. 2020;10(11):1722-1741. doi: 10.1158/2159-8290.CD-20-0160. Epub Jul. 23, 2020. [cited by applicant]
Buss, Meghan C. et al., The WIP1 oncogene promotes progression and invasion of aggressive medulloblastoma variants, Oncogene. Feb. 26, 2015;34(9):1126-40. doi: 10.1038/onc.2014.37. Epub Mar. 17, 2014. [cited by applicant]
Arck PC. et al., Towards a ‘free radical theory of graying’: melanocyte apoptosis in the aging human hair follicle is an indicator of oxidative stress induced tissue damage. FASEB J. 2006;20:1567-9. [cited by applicant]
Xu, Cheng et al., P53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist, Acta Neuropathol Commun. Nov. 3, 2021;9(1):178. doi: 10.1186/s40478-021-01270-y. [cited by applicant]
Kim, Jinchul et al., Wild-Type p53 Promotes Cancer Metabolic Switch by Inducing PUMA-Dependent Suppression of Oxidative Phosphorylation. Cancer Cell Feb. 11, 2019;35(2):191-203.e8. doi: 10.1016/j.ccell.2018.12.012. Epub… [cited by applicant]
Katsuoka, K. et al., Effects of epidermal growth factor, fibroblast growth factor, minoxidil and hydrocortisone on growth kinetics in human hair bulb papilla cells and root sheath fibroblasts cultured in vitro; 1987; 27… [cited by applicant]
Lacouture, M.E. et al., Breast Cancer Res Treat Feb; 186(1):107-114 2021. [cited by applicant]
Takashima, Iwao et al., Biology and Disease of Hair; Comparative Study of Hair Growth in Mammals, with Special References to Hair Grouping and Hair Cycle; and Hair Growth Rate in the Juvenile Stumptailed Macaque; Baltim… [cited by applicant]
Moore, G.P.M et al., J. Endocrinology; Effects of Epidermal Growth Factor on Hair Growth In the Mouse; 88:293-299, 1981. [cited by applicant]
Feldman et al., Zinc Fingers and Vitamin D Resistance, The Lancet, Mar. 4, 1989, p. 478. Molecular and Cellular Endocrinology, 72 (1990) pp. 57-62. [cited by applicant]